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DISCUSSION
Dr Phillip Levin (Los Angeles, Calif). Dr Gibson’s elegant
and comprehensive presentation on the use of endovenous abla-
tion for short saphenous vein reflux indicates that this methodol-
ogy can be expanded to the treatment of the short saphenous vein
incompetence with very limited complications and excellent re-
sults. Furthermore, the paper provides some clarity on how the risk
of DVT after short saphenous vein surgery can be reduced. Let me
say at the outset that I have had no experience with EVLT, having
elected to use radiofrequency ablation because that modality had a
decreased incidence of perforation and allows for the continuous
feedback of treatment parameters, which indicate ongoing effec-
tiveness of ablation. Be that as it may, intermediate-term results of
both methods are similar and both are more effective than ligation
and stripping.
Dr Gibson and her colleagues’ experience of treating 210
short saphenous veins over the past 1½ years is remarkable when
compared with our experience in Los Angeles, where out of the
276 limbs that we treated with radiofrequency ablation, only 10
short saphenous veins were ablated, of which one developed a
small popliteal clot, which brings me to the first series of questions.
How many greater saphenous veins underwent EVLT during
the same study period? What were the criteria for treating short
saphenous veins, and how did you distinguish the short saphenous
vein as the main source of varicosities, skin changes, or ulcerations?
I noted that 78% of the limbs treated also had concomitant
treatment of the greater saphenous vein and 64% had adjunctive
treatment with perforator ligation. Would those two procedures
alone have relieved the patients of their varicosities?
I routinely perform the old tourniquet test during my initial
examination of patients with varicose veins to determine if the
varicosities fill with an above-knee tourniquet in place. If they do
not, then reflux is most likely proximal to the short saphenous vein,
which needs no treatment even if the ultrasound shows incompe-
tence.
Over 130 years ago, Giacomini described the vagaries of the
saphenopopliteal junction. Dr Gibson’s paper not only reaffirms
Giacomini’s findings but also gives them critical importance for
today’s vascular surgeon interested in treating the short saphenous
vein.
There is little doubt that the low incidence of DVT following
ablation of the greater saphenous vein is related to the consistency
of the anatomy at the saphenofemoral junction along with main-
taining patency of the superficial epigastric and the superficial
circumflex iliac veins during ablation. This is supported by your
previously unpublished low incidence of DVT following greater
saphenous vein ablation and confirmed by a 1.8% incidence in our
series. Your relatively high incidence of DVT in this series raises
concerns regarding ablation or even ligation of the short saphe-
nous vein. Would you recommend treatment of a patient with type
A anatomy, and if so, would you routinely offer prophylactic
anticoagulation?
Finally, I was intrigued by the fact that only 16% of the patients
in this series underwent microphlebectomy, because in our series,
over 90% had this adjunctive procedure in order to avoid subse-
quent surgery and treatment. I note that 29% of the patients in
your series required secondary procedures such as microphlebec-
tomy and sclerotherapy. Do the majority of varicose veins disap-
pear after ablation alone, and how do your patients accept under-
going additional therapies including surgery?
I want to congratulate the authors on an excellent and stimu-
lating paper and thank the society for the privilege of discussing it.
DrKathleen Gibson. Addressing your first question, approx-
imately 1000 great saphenous veins were treated during the same
period. In agreement with anatomic studies, roughly 20% of our
patients with venous insufficiency have small saphenous vein in-
volvement that requires treatment.
How did we determine which patients needed treatment? We
have a vascular lab associated with our practice, and our vascular
technologists are very good at vein mapping. They draw diagrams
similar to those that Dr Bergen’s group showed yesterday. We find
that there are many patients that have some “trickle reflux” or a
mild incompetence in the small saphenous vein or a branch coming
over from the great saphenous vein where the proximal small
saphenous is not incompetent. I refer to those veins as “innocent
bystander” small saphenous veins and feel they do not need treat-
ment, as often the patients have good results with only treatment of
the GSV. The patients need to have symptoms referable to the SSV
or we have to see large varicosities coming off of the SSV on duplex
evaluation. Just seeing reflux in and of itself does not mandate
treatment of the SSV.
About two thirds of our patients had microphlebectomy or
perforator ligation. Determining when and if to perform this
depends on how large the branches are coming off of the vein and
the patient’s goals. If the patient’s goals are cosmesis, I am more
likely to do more microphlebectomy or sclerotherapy. If they are
having the procedure because of pain or ulceration and do not
really have a concern whether every small blue vein in the back of
the calf is visible or not, I will do less; and I will do whatever I think
needs to be done to make them symptomatically better.
In terms of whether or not we are going to be treating type A
anatomy with prophylactic anticoagulation, I just finished this
analysis last month and my group is in discussion about whether or
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not we should be treating these patients with prophylactic antico-
agulation. You do, however, have to weigh the fact that all patients
did pretty well even if they were treated after the DVT was
discovered rather than being treated prophylactically. We wonder
whether we would have more complications from anticoagulation
if we prophylactically treat all patients with type A anatomy. I do
use this data when I counsel patients about their risk because many
patients are concerned about deep vein blood clot and want to
know what their risk is, and I can counsel them based on their
anatomy about the likelihood that they will have a clot.
Your final question was, do the majority of the branches go
away, and if they do not, how is patient acceptance with needing
other procedures. I think that counseling them ahead of time
about what you are going to do and what they might expect is very
important. For example, the patient shown in this slide had scle-
rotherapy at the same time as her venous ablation. She had pain but
also was very concerned about the way her leg looked, and she
ended up with an excellent cosmetic result.
This patient, on the other hand, if you look closely, you can
still see some visible varicosities in the photo. On the digital
photograph after treatment she did have some visible varicosities. I
did not perform any sclerotherapy on her limb because she was an
elderly woman, was not concerned about the way the back of her
leg looked, and just wanted the edema and the pain to be better. I
think as long as you are very honest with patients up front, they do
fine with having follow-up procedures.
Dr John Bergan (LaJolla, Calif). This is an excellent paper,
and I would like to compliment Dr Gibson not only on the
presentation but also for the careful analysis, and most of all for
taking the surgery of varicose veins out of the popliteal fossa. There
is danger there. This is a technique that keeps the surgeon out of
the popliteal fossa, avoids nerve injury, and does ablate the short
saphenous vein.
Your percentage of cases was correctly correct. In 1000 vein
cases, you had about 200 small saphenous cases. So that was
proper, and I think your duplex analysis was excellent, although we
found different findings. It does not matter. You have done a
careful mapping.
The only question I have really has to do with nerve injury.
Mike Dalsing at Indiana University had a neurologist look at his
patients after saphenous surgery, and he found a rather high
incidence of nerve injury. So the question is did the surgeon
evaluate the patient after surgery or was there an objective exam-
iner, preferably a neurologist?
This is really a good study. I am pleased that you presented it,
and I hope to see it in print. Again, the program committee was
wise to pick this paper.
DrGibson. Thank you for your kind comments. In answer to
your questions, we did not have a neurologist evaluate the patient.
It was the surgeon at the 6-week visit asking the patient whether
they had any numbness or paresthesias and then performing a
“light touch” physical examination. Certainly, with any future
work it might be more relevant to have an independent examiner.
DrTimothy Liem (Portland, Ore). Kathy, I enjoyed that very
much. I think your data, regarding the variations in the anatomy of
the saphenopopliteal junction, has helped me to counsel my pa-
tients with regard to the risk for DVT when they are having small
saphenous.
Dr Lowell Kabnick has previously described a classification
system for DVTs in patients who are having saphenous ablation.
He provided some guidelines regarding how far the clot protrudes
into the lumen of either the femoral or the popliteal vein, and the
treatment recommendations varied according to that. My first
question is what do you think about a particular classification
system like that?
My second question is about hypercoagulable conditions.
Some studies indicate that in patients who present with venous
stasis ulcers, there may be a prevalence of at least 20% for factor V
Leiden. I do not know what to do with that data. I do not think
that everyone needs to be tested for thrombophilia beforehand, or
afterward in patients who have DVT after having had small saphe-
nous ablation. I also wanted to comment on your reference to Dr
Proebstle’s initial article with his one DVT complication. That
patient also had a clotting disorder with a platelet count that was
markedly elevated.
Dr Gibson. Thank you. We do not use Dr Kabnick’s recom-
mendations; however, we do have our own criteria that we use for
the great saphenous vein. If the clot is protruding 0.4 mm or less,
we observe it; and if it is more, then we treat it. Typically length of
treatment is 6 weeks or less, however. Having these data now, we
may develop criteria as well that may be similar for the small
saphenous vein.
Your second question about whether or not these patients had
hypercoagulable states, we did not do routine testing on patients.
Interestingly, none of the 10 limbs with the ulcers had DVTs, but
that is an interesting thought. I have treated a number of patients
with known factor V Leiden, both with great and small saphenous
vein laser ablation, and I have treated them with Lovenox on the
day of the procedure. We have had no DVTs in any of those
patients. Whether or not they would have had it without Lovenox,
I do not know but it would be an interesting question.
Dr Elna Masuda (Honolulu, Hawaii). I really enjoyed this
wonderful paper that you presented, Kathy. I have a question
regarding where you placed the tip of the laser. We have experience
at hospital primarily with great saphenous vein ablation with laser,
angiodynamic laser, andwhat we found is there is an injury distance
from the tip of the laser that is about 1 to 2 cm beyond the tip, and
that injury zone is not really well described by the manufacturer.
Although we used to place the tip at 1 cm, because they say 1 to 2
cm, we had DVTs from that. In your series, you pointed out that
you placed the tip at 2 to 3 cm. Was that truly the site of laser
treatment? Because after tumescence you can see sometimes that
the laser tip protrudes forward, ormarches forward, and could have
injured the popliteal vein.
Dr Gibson. Good point. We always check the tip of the laser
after tumescence. We do check before and after. Also, if the patient
moves their leg at all during the procedure, it can move the laser
tip, so we always double-check it before we fire the laser. The
distance really depended on the anatomy. For type C, of course, it
does not matter; you can go all the way up into the thigh if you
want to. For type B, we tried to preserve that Giacomini however
far back it came in, and so we would go 2 to 3 cm sometimes back
from that. For type A, as the small saphenous vein curves, the laser
will not really follow that curve well, so you place the laser tip right
where it takes the curve deep to the popliteal vein, and usually, that
is 2 to 3 cm back for the saphenopopliteal junction, sometimes
even further. We had more clots early in the study, and I think that
early in the study the laser tip might have been closer to the
junction. That might be why we had more clots early than late.
Dr Rajabrata Sarkar (San Francisco, Calif). I have two tech-
nical questions. You did adjunctive phlebectomy. During any kind
of endovenous ablation, tumescence is very important to protect
the nerve. We find that tumescence distorts the varicosity, so did
you do the adjunctive procedure before you tumesced? That’s my
first question.
My second question is the laser uses hemoglobin as the
chromophore to convert to heat. Do you think if you anticoagulate
these patients, as you have discussed previously, you will have a
higher rate of recanalization or treatment failure because you will
disturb the clot that is sealing the vein? Thank you.
Dr Gibson. To answer the first question, yes, tumescence
does distort evenmore than for microphlebectomy, because I mark
all the vein branches ahead of time with the patient standing. For
sclerotherapy, tumescence makes it almost impossible. What I will
usually do if I am going to be doing sclerotherapy at the same time
is do tumescence proximally and perform laser on the very proxi-
mal part of the vein, as Dr Bergen was discussing yesterday. You do
not want a lot of foam sclerosant getting into the deep system, so
you can seal proximally with the laser, perform sclerotherapy, and
then complete the tumescence for the rest of the length of the vein.
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You can then complete the laser procedure; or, if I am performing
microphlebectomy, sometimes I will inject local anesthetic, make
small nicks in the skin over the vein, use a very tiny mosquito, and
clamp the vein so that after I complete the tumescence I already
have the vein “hooked” and can finish the microphlebectomy. I
find that actually the tumescence helps with patient comfort for the
microphlebectomy as well, and you do not need to use as much
local anesthetic in the skin.
Your second question was about anticoagulation and would
we have increased rate of recanalization. I am not sure about that,
but I do not think so because when we do the laser procedure, we
have the patient in reverse Trendelenburg. We try to empty the
vein as much as possible to have the laser in contact with the vein
wall, so I think not only does the interaction with hemoglobin
cause closure of the vein but it is actually a direct endothelial injury
as well.
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